BR112019012140A2 - composto, composição farmacêutica, método para prevenir ou tratar um distúrbio sanguíneo, método para prevenir ou tratar um câncer e uso de um composto - Google Patents
composto, composição farmacêutica, método para prevenir ou tratar um distúrbio sanguíneo, método para prevenir ou tratar um câncer e uso de um composto Download PDFInfo
- Publication number
- BR112019012140A2 BR112019012140A2 BR112019012140-4A BR112019012140A BR112019012140A2 BR 112019012140 A2 BR112019012140 A2 BR 112019012140A2 BR 112019012140 A BR112019012140 A BR 112019012140A BR 112019012140 A2 BR112019012140 A2 BR 112019012140A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- alkyl
- halo
- petition
- compound according
- Prior art date
Links
- 0 *c1cc(*)c(*)cc1 Chemical compound *c1cc(*)c(*)cc1 0.000 description 21
- JQERBLHDQHWDFD-UHFFFAOYSA-N CC(C(OC)=O)(N)N Chemical compound CC(C(OC)=O)(N)N JQERBLHDQHWDFD-UHFFFAOYSA-N 0.000 description 1
- ZELBRZDFYSYCCH-UHFFFAOYSA-N Cc1cc(NC)nc(Nc(cc2)cc(-[n]3ncc4c3CCNC4)c2OC)n1 Chemical compound Cc1cc(NC)nc(Nc(cc2)cc(-[n]3ncc4c3CCNC4)c2OC)n1 ZELBRZDFYSYCCH-UHFFFAOYSA-N 0.000 description 1
- KFPUSYLKMFOMAA-UHFFFAOYSA-N Cc1cc(NC)nc(Nc(cc2)cc(N3N(C)CC(C=O)=C3)c2OC)n1 Chemical compound Cc1cc(NC)nc(Nc(cc2)cc(N3N(C)CC(C=O)=C3)c2OC)n1 KFPUSYLKMFOMAA-UHFFFAOYSA-N 0.000 description 1
- NNIMBONYQUFXSK-UHFFFAOYSA-N Cc1cc(NC)nc(Nc(cc2)cc(N3N(C)CC(CN(C)C)=C3)c2OC)n1 Chemical compound Cc1cc(NC)nc(Nc(cc2)cc(N3N(C)CC(CN(C)C)=C3)c2OC)n1 NNIMBONYQUFXSK-UHFFFAOYSA-N 0.000 description 1
- BWSQVSJRRUEOBL-UHFFFAOYSA-N Cc1cncc2n[o]cc12 Chemical compound Cc1cncc2n[o]cc12 BWSQVSJRRUEOBL-UHFFFAOYSA-N 0.000 description 1
- SEEMCOFDEYZWKO-UHFFFAOYSA-N NCCN1C2=CN=NC2=CC=C1 Chemical compound NCCN1C2=CN=NC2=CC=C1 SEEMCOFDEYZWKO-UHFFFAOYSA-N 0.000 description 1
- MJEPPEQNLZSPAP-UHFFFAOYSA-N Nc1c2ncccc2n[nH]1 Chemical compound Nc1c2ncccc2n[nH]1 MJEPPEQNLZSPAP-UHFFFAOYSA-N 0.000 description 1
- KBUPOWQDHWCTJT-UHFFFAOYSA-N Nc1cncc2c[o]nc12 Chemical compound Nc1cncc2c[o]nc12 KBUPOWQDHWCTJT-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- QAZSWCJDGUNYHQ-UHFFFAOYSA-N Sc1cc2c[o]nc2nc1 Chemical compound Sc1cc2c[o]nc2nc1 QAZSWCJDGUNYHQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436139P | 2016-12-19 | 2016-12-19 | |
| US201762517840P | 2017-06-09 | 2017-06-09 | |
| PCT/US2017/067192 WO2018118842A1 (en) | 2016-12-19 | 2017-12-19 | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019012140A2 true BR112019012140A2 (pt) | 2019-11-05 |
Family
ID=60972416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019012140-4A BR112019012140A2 (pt) | 2016-12-19 | 2017-12-19 | composto, composição farmacêutica, método para prevenir ou tratar um distúrbio sanguíneo, método para prevenir ou tratar um câncer e uso de um composto |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20200039998A1 (enExample) |
| EP (2) | EP3555070B1 (enExample) |
| JP (2) | JP2020504715A (enExample) |
| KR (1) | KR102693367B1 (enExample) |
| CN (2) | CN110088099B (enExample) |
| AU (3) | AU2017382830A1 (enExample) |
| BR (1) | BR112019012140A2 (enExample) |
| CA (1) | CA3045032A1 (enExample) |
| CL (2) | CL2019001664A1 (enExample) |
| CO (1) | CO2019006787A2 (enExample) |
| DK (1) | DK3555070T3 (enExample) |
| ES (1) | ES2955132T3 (enExample) |
| FI (1) | FI3555070T3 (enExample) |
| HU (1) | HUE063405T2 (enExample) |
| IL (1) | IL267090A (enExample) |
| LT (1) | LT3555070T (enExample) |
| MA (1) | MA47233A (enExample) |
| MX (1) | MX2019007234A (enExample) |
| PL (1) | PL3555070T3 (enExample) |
| PT (1) | PT3555070T (enExample) |
| SG (1) | SG10201913464TA (enExample) |
| SI (1) | SI3555070T1 (enExample) |
| TW (2) | TW202411220A (enExample) |
| WO (1) | WO2018118842A1 (enExample) |
| ZA (1) | ZA201904234B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| US20200039961A1 (en) * | 2016-09-30 | 2020-02-06 | Epizyme, Inc. | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |
| PE20191349A1 (es) * | 2017-02-14 | 2019-09-30 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos |
| US20200113901A1 (en) * | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| WO2019014402A1 (en) | 2017-07-14 | 2019-01-17 | Innate Tumor Immunity, Inc. | MODULATORS OF NLRP3 |
| WO2019079485A1 (en) * | 2017-10-17 | 2019-04-25 | Epizyme, Inc. | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF |
| AU2018353150B2 (en) * | 2017-10-18 | 2024-06-06 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in treating or preventing blood disorders |
| MA50418A (fr) * | 2017-10-18 | 2021-04-07 | Epizyme Inc | Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| CA3117169A1 (en) | 2018-10-24 | 2020-04-30 | Effector Therapeutics, Inc. | Crystalline forms of mnk inhibitors |
| WO2020097398A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12338228B2 (en) * | 2019-01-14 | 2025-06-24 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| US12433867B2 (en) | 2019-02-22 | 2025-10-07 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
| MX2021011699A (es) * | 2019-03-28 | 2022-01-18 | Epizyme Inc | Derivados de quinolina y su uso para el tratamiento del cancer. |
| CA3145391A1 (en) | 2019-06-27 | 2020-12-30 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| CA3181537A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CN115160297B (zh) | 2020-12-22 | 2023-03-31 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| WO2022140527A1 (en) | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| AU2022366869A1 (en) * | 2021-10-15 | 2024-05-02 | Tango Therapeutics, Inc. | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
| TW202325289A (zh) | 2021-11-09 | 2023-07-01 | 美商雅捷可斯治療公司 | Ｊａｋ２抑制劑之形式及組合物 |
| TW202334139A (zh) | 2021-11-09 | 2023-09-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑 |
| KR20250040981A (ko) * | 2022-07-20 | 2025-03-25 | 주식회사 에스투시바이오 | 헤테로아릴 유도체 화합물 및 이의 용도 |
| CN115974727B (zh) * | 2023-01-17 | 2024-03-12 | 青岛前线生物工程有限公司 | 一种联苯肼酯的合成方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| EP1126843A4 (en) * | 1998-10-29 | 2005-06-15 | Bristol Myers Squibb Co | AMINO-CELL DERIVATIVE COMPOUNDS INHIBITORS OF ENZYME IMPDH |
| ATE337312T1 (de) * | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
| WO2003040141A1 (en) * | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| ES2365223T3 (es) * | 2003-08-07 | 2011-09-26 | Rigel Pharmaceuticals, Inc. | Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos. |
| JP2009501164A (ja) * | 2005-07-15 | 2009-01-15 | ４エスツェー アクチェンゲゼルシャフト | ２−アリールベンゾチアゾール及びその使用 |
| MEP3808A (xx) * | 2005-12-21 | 2010-02-10 | Novartis Ag | Derivati pirimidinil aril uree kao fgf inhibitori |
| TW200902010A (en) * | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
| WO2009012421A1 (en) * | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| MX2010008700A (es) * | 2008-02-22 | 2010-08-30 | Hoffmann La Roche | Moduladores de beta-amiloide. |
| SG172885A1 (en) * | 2009-01-23 | 2011-08-29 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway |
| US8367689B2 (en) * | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
| CN104640863B (zh) * | 2012-09-20 | 2016-06-08 | 山东亨利医药科技有限责任公司 | 嘧啶胺衍生物及其制备方法和应用 |
| CA2892677A1 (en) * | 2012-12-04 | 2014-06-12 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CA2904610A1 (en) * | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| US20160009694A1 (en) * | 2013-03-15 | 2016-01-14 | Portola Pharmaceuticals, Inc. | Cyclohexanediamine compounds and methods for their preparation |
| WO2016175264A1 (ja) * | 2015-04-28 | 2016-11-03 | カルナバイオサイエンス株式会社 | 抗マラリア活性を有する新規ヘテロアリール誘導体 |
| EP3442947B1 (en) * | 2016-04-15 | 2023-06-07 | Epizyme, Inc. | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| CN106083828A (zh) * | 2016-06-30 | 2016-11-09 | 浙江大学 | 含吖丙啶环侧链的芳胺嘧啶衍生物及制备和应用 |
-
2017
- 2017-12-19 EP EP17829454.2A patent/EP3555070B1/en active Active
- 2017-12-19 US US16/471,151 patent/US20200039998A1/en not_active Abandoned
- 2017-12-19 TW TW112121399A patent/TW202411220A/zh unknown
- 2017-12-19 HU HUE17829454A patent/HUE063405T2/hu unknown
- 2017-12-19 SI SI201731407T patent/SI3555070T1/sl unknown
- 2017-12-19 AU AU2017382830A patent/AU2017382830A1/en not_active Abandoned
- 2017-12-19 EP EP23186749.0A patent/EP4285906A3/en not_active Withdrawn
- 2017-12-19 DK DK17829454.2T patent/DK3555070T3/da active
- 2017-12-19 CA CA3045032A patent/CA3045032A1/en active Pending
- 2017-12-19 LT LTEPPCT/US2017/067192T patent/LT3555070T/lt unknown
- 2017-12-19 KR KR1020197020233A patent/KR102693367B1/ko active Active
- 2017-12-19 PL PL17829454.2T patent/PL3555070T3/pl unknown
- 2017-12-19 CN CN201780078660.3A patent/CN110088099B/zh active Active
- 2017-12-19 SG SG10201913464TA patent/SG10201913464TA/en unknown
- 2017-12-19 WO PCT/US2017/067192 patent/WO2018118842A1/en not_active Ceased
- 2017-12-19 JP JP2019530439A patent/JP2020504715A/ja active Pending
- 2017-12-19 ES ES17829454T patent/ES2955132T3/es active Active
- 2017-12-19 TW TW106144660A patent/TWI808067B/zh active
- 2017-12-19 BR BR112019012140-4A patent/BR112019012140A2/pt not_active Application Discontinuation
- 2017-12-19 MA MA047233A patent/MA47233A/fr unknown
- 2017-12-19 MX MX2019007234A patent/MX2019007234A/es unknown
- 2017-12-19 CN CN202310013963.4A patent/CN116041346A/zh active Pending
- 2017-12-19 PT PT178294542T patent/PT3555070T/pt unknown
- 2017-12-19 FI FIEP17829454.2T patent/FI3555070T3/fi active
-
2019
- 2019-06-04 IL IL267090A patent/IL267090A/en unknown
- 2019-06-17 CL CL2019001664A patent/CL2019001664A1/es unknown
- 2019-06-26 CO CONC2019/0006787A patent/CO2019006787A2/es unknown
- 2019-06-27 ZA ZA2019/04234A patent/ZA201904234B/en unknown
-
2020
- 2020-04-29 CL CL2020001133A patent/CL2020001133A1/es unknown
-
2021
- 2021-11-15 US US17/526,058 patent/US20220235065A1/en not_active Abandoned
-
2022
- 2022-04-14 AU AU2022202494A patent/AU2022202494B2/en active Active
- 2022-05-16 JP JP2022080211A patent/JP2022110080A/ja active Pending
-
2024
- 2024-08-01 AU AU2024205290A patent/AU2024205290A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019012140A2 (pt) | composto, composição farmacêutica, método para prevenir ou tratar um distúrbio sanguíneo, método para prevenir ou tratar um câncer e uso de um composto | |
| JP7425724B2 (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 | |
| AU2021277619B2 (en) | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors | |
| WO2020186220A1 (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| BR112020007632A2 (pt) | composto, composição farmacêutica, método para inibir um dentre ou tanto ehmt1 quanto ehmt2, método para prevenir ou tratar um distúrbio sanguíneo, método para prevenir ou tratar um câncer e uso do composto | |
| HK40098892A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| HK40016100B (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| HK40016100A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| OA19666A (en) | Amine-substituted heterocyclic compounds as Ehmt2 inhibitors and methods of use thereof. | |
| HK40012431A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| NZ795530A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| HK40012431B (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |